We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Astellas Pharma Inc (PK) | USOTC:ALPMY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.21 | -2.12% | 9.68 | 9.53 | 9.92 | 9.756 | 9.68 | 9.70 | 94,828 | 22:00:01 |
From Feb 2022 to Feb 2025
By Colin Kellaher
Shares of Taysha Gene Therapies Inc. surged more than 45% in premarket trading Tuesday after Japan's Astellas Pharma Inc. agreed to invest $50 million for a 15% stake, supporting the advancement of Taysha's gene-therapy development programs.
Dallas-based Taysha said it is granting Astellas an exclusive option to license two clinical-stage programs for rare monogenic central-nervous-system diseases: TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy.
Taysha, which reported cash and equivalents of $66.2 million as of June 30, said it also granted Astellas certain rights related to any potential change of control.
Taysha shares, which closed Monday at $1.51, were recently up nearly 46% to $2.20 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 25, 2022 06:11 ET (10:11 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astellas Pharma (PK) Chart |
1 Month Astellas Pharma (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
